Intrathecal 5-fluorouracil in the rhesus monkey.
Because meningeal spread of both leukemia and solid tumors remains a difficult therapeutic problem, there is a compelling need to develop new agents for intrathecal administration. 5-Fluorouracil (5FU), an active anticancer agent, penetrates into the central nervous system to some degree following intravenous dosing. Significant systemic toxicity, however, is associated with this route of administration. Therefore, the pharmacokinetic behavior of 5FU following its intrathecal administration was studied in a rhesus monkey model. After a 10-mg intraventricular dose, the disappearance of the drug from ventricular cerebrospinal fluid was monoexponential, the half-life being 51 min; the area under the concentration-time curve (AUC) being greater than 18 mM h-1; and the peak ventricular 5FU concentrations ranging between 10 and 15 mM. After a 1-mg intralumbar dose, the AUC was 1235 microM h-1. No toxicity was observed following intraventricular administration of 5FU. After intralumbar administration of either a 10-mg or a 1-mg dose, however, local toxicity was observed in the lumbar spinal cord. These findings suggest that intrathecal administration of 5FU is not presently a feasible means of achieving cytotoxic cerebrospinal fluid concentrations.
Berg
S L
SL
Pediatric Branch, National Cancer Institute, Bethesda, MD 20892.
Balis
F M
FM
McCully
C L
CL
Parker
G A
GA
Murphy
R F
RF
Poplack
D G
DG
D000818:Animals; D002552:Cerebral Ventricles / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage / Q000134:cerebrospinal fluid* / Q000493:pharmacokinetics* / Q000633:toxicity; D007278:Injections, Spinal; D008253:Macaca mulatta; D008297:Male; D009336:Necrosis / Q000139:chemically induced; D010243:Paralysis / Q000139:chemically induced; D013116:Spinal Cord / Q000378:metabolism / Q000473:pathology
D005472:Fluorouracil